title: Reduced midazolam clearance must be considered in prolonged coma.
authors.forename: R
authors.initials: R
authors.lastname: Meierhans
authors.forename: J F
authors.initials: JF
authors.lastname: Stover
authors.forename: M
authors.initials: M
authors.lastname: Béchir
authors.forename: M
authors.initials: M
authors.lastname: Keel
authors.forename: R
authors.initials: R
authors.lastname: Stocker
mesh_terms: D000328:Adult; D018686:Anesthetics, Intravenous / Q000097:blood / Q000493:pharmacokinetics*; D000931:Antidotes / Q000008:administration & dosage; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage; D003128:Coma / Q000139:chemically induced*; D005442:Flumazenil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008874:Midazolam / Q000097:blood / Q000493:pharmacokinetics*; D009270:Naloxone / Q000008:administration & dosage; D009292:Narcotic Antagonists / Q000008:administration & dosage; D010830:Physostigmine / Q000008:administration & dosage; D013995:Time
chemical_list: D018686:Anesthetics, Intravenous; D000931:Antidotes; D002800:Cholinesterase Inhibitors; D009292:Narcotic Antagonists; D009270:Naloxone; D005442:Flumazenil; D010830:Physostigmine; D008874:Midazolam